查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612995

臨床化學和免疫診斷市場：按產品類型、最終用戶分類 - 全球預測 2025-2030

Clinical Chemistry & Immunodiagnostic Market by Product Type (Instruments, Reagents), End-user (Diagnostic Laboratories, Hospitals) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年臨床化學和免疫診斷市值為376.7億美元，預計到2024年將達到400.1億美元，複合年成長率為6.41%，到2030年將達到582億美元。

臨床化學和免疫診斷市場包括專注於分析體液以進行診斷和健康監測的醫療測試程序。由於慢性病的流行、人口老化和個人化醫療的出現，這一領域變得至關重要。應用範圍涵蓋疾病診斷、藥物開發和病患監測，為包括醫院、診斷實驗室、研究機構和就地檢驗設施在內的各種最終用戶提供服務。生物標記發現、實驗室自動化以及人工智慧在診斷中的整合的進步正在推動成長。一個顯著的商機在於開發經濟高效且快速的 POC 測試解決方案，以提高偏遠和資源匱乏環境中的可近性。使用基因組學、蛋白質組學和代謝體學的個人化診斷也提供了精確的醫療保健解決方案並擴大了市場視野。阻礙市場擴張的挑戰包括監管障礙、高昂的研發成本和複雜的醫療設備報銷。資料隱私問題以及對熟練專業人員管理先進診斷技術的需求進一步增加了複雜性。儘管存在這些挑戰，用於資料分析的機器學習演算法的創新、診斷設備的小型化以及測試靈敏度和特異性的改進提供了重要的成長途徑。這個市場的動態本質很大程度上是由快速的技術進步和監管適應決定的，需要業務策略制定的靈活性。促進與學術機構的研究合作和參與官民合作關係關係可以促進成長，同時投資強力的培訓計畫以縮小技能差距。隨著市場競爭的激烈，企業應專注於透過併購鞏固自身地位，擴大產品系列，並利用客戶回饋進行創新。不斷開拓開拓的市場並調整解決方案以服務世界各地不同的經濟領域對於在不斷變化的市場格局中保持成長和獲得競爭優勢至關重要。

主要市場統計
基準年[2023] 376.7億美元
預測年份 [2024] 400.1億美元
預測年份 [2030] 582億美元
複合年成長率（%） 6.41%

市場動態：快速發展的臨床化學和免疫診斷市場的關鍵市場洞察

供需的動態交互作用正在改變臨床化學和免疫診斷市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 老年人口增加和慢性病盛行率
    • 政府積極採用臨床化學和免疫診斷技術
    • 就地檢驗的重要性和意識不斷增強
  • 市場限制因素
    • 化學和免疫診斷產品的回想問題
  • 市場機會
    • 臨床化學和免疫診斷設備的持續技術進步
    • 臨床化學和免疫診斷在遠端醫療和個人化治療的潛力不斷增加
  • 市場挑戰
    • 產品開發和商業化監管標準的嚴格性和多樣性

波特五力：駕馭臨床化學和免疫診斷市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解臨床化學和免疫診斷市場的外部影響

外部宏觀環境因素在塑造臨床化學和免疫診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析了解臨床化學和免疫診斷市場的競爭格局

臨床化學和免疫診斷市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣臨床化學和免疫診斷市場供應商的績效評估

FPNV定位矩陣是評估臨床化學和免疫診斷市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製臨床化學和免疫診斷市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，臨床化學和免疫診斷市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 老年人口增加和慢性病增加
      • 政府對引進臨床化學和免疫診斷技術的積極努力
      • 就地檢驗的重要性和意識不斷增強
    • 抑制因素
      • 與化學和免疫診斷產品召回相關的問題
    • 機會
      • 臨床化學和免疫診斷設備的持續技術進步
      • 擴大臨床化學和免疫診斷在遠端醫療和個人化治療的潛力
    • 任務
      • 產品開發和商業化嚴格且多樣化的監管標準
  • 市場區隔分析
    • 產品類型：採用模組化、可擴展的系統，可輕鬆與現有醫院資訊系統整合
    • 最終用戶：更加關注設備中的先進技術整合
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章臨床化學和免疫診斷市場：按產品類型

  • 裝置
  • 試劑

第7章臨床化學和免疫診斷市場：按最終用戶

  • 診斷實驗室
  • 醫院

第8章美洲臨床化學和免疫診斷市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太臨床化學和免疫診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲的臨床化學和免疫診斷市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Beckman Coulter DxC 500 AU 化學分析儀簡介
    • FUJIREBIO Holdings 與 Agappe Diagnostics 結成戰略聯盟，徹底改變印度的化學冷光免疫檢測生產
    • 羅氏透過收購 LumiraDx 照護端技術擴大診斷產品組合
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Accurex Biomedical Private Limited
  • Agappe Diagnostics Ltd.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Cardinal Health, Inc.
  • Chengdu Seamaty Technology Co., Ltd.
  • Danaher Corporation
  • DiaSorin SpA
  • ELITechGroup by Bruker Corporation
  • F. Hoffmann-La Roche Ltd.
  • GenviewDX
  • HU Group Holdings Inc.
  • Hitachi, Ltd.
  • HORIBA, Ltd.
  • Immuno Diagnostics Pvt. Ltd.
  • Medix Biochemica AB
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • QuidelOrtho Corporation
  • Sekisui Medical Co. Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Siemens AG
  • Thermo Fisher Scientific Inc.
  • viSole The Solution
Product Code: MRR-CB04E0565D32

The Clinical Chemistry & Immunodiagnostic Market was valued at USD 37.67 billion in 2023, expected to reach USD 40.01 billion in 2024, and is projected to grow at a CAGR of 6.41%, to USD 58.20 billion by 2030.

The Clinical Chemistry & Immunodiagnostic market involves medical testing procedures that focus on analyzing bodily fluids for diagnostic and health monitoring purposes. This sector is integral due to chronic disease prevalence, aging populations, and the advent of personalized medicine. Applications span disease diagnosis, drug development, and patient monitoring, serving diverse end-users such as hospitals, diagnostic labs, research institutions, and point-of-care testing facilities. Growth is fueled by advancements in biomarker discovery, automation in laboratories, and the integration of artificial intelligence in diagnostics. A notable opportunity lies in developing cost-effective, rapid point-of-care testing solutions to enhance accessibility in remote or resource-poor settings. Personalized diagnostics, which leverage genomics, proteomics, and metabolomics, are also expanding the market's horizon, offering precise healthcare solutions. Challenges hindering market expansion include regulatory obstacles, high RD costs, and complexities in medical device reimbursement. Data privacy concerns and the need for skilled professionals to manage sophisticated diagnostic technologies add further layers of complexity. Despite these challenges, innovation in machine learning algorithms for data analysis, miniaturization of diagnostic devices, and enhancing the sensitivity and specificity of tests present significant growth avenues. The dynamic nature of this market is largely shaped by rapid technological progress and regulatory adaptations, demanding agility in strategy formulation for companies. Fostering collaborations with academic institutions for research and engaging in public-private partnerships could catalyze growth, alongside investing in robust training programs to bridge skill gaps. As the market is highly competitive, businesses should focus on consolidating their positions through mergers and acquisitions, expanding their product portfolios, and leveraging customer feedback to innovate. Continuous exploration of untapped markets and the adaptation of solutions to cater to varied economic segments worldwide will be crucial in sustaining growth and gaining a competitive edge in this evolving market landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 37.67 billion
Estimated Year [2024] USD 40.01 billion
Forecast Year [2030] USD 58.20 billion
CAGR (%) 6.41%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Clinical Chemistry & Immunodiagnostic Market

The Clinical Chemistry & Immunodiagnostic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising elderly population and growing prevalence of chronic diseases
    • Favorable government initiatives for adoption of clinical chemistry & immunodiagnostic techniques
    • Growing importance and awareness of point-of-care testing
  • Market Restraints
    • Issues associated with chemistry and immunodiagnostic product recall
  • Market Opportunities
    • Ongoing technological advancements in clinical chemistry and immunodiagnostic instruments
    • Growing potential of clinical chemistry & immunodiagnostic in telemedicine and personalized therapies
  • Market Challenges
    • Stringent and varying regulatory standards for product development and commercialization

Porter's Five Forces: A Strategic Tool for Navigating the Clinical Chemistry & Immunodiagnostic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Clinical Chemistry & Immunodiagnostic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Clinical Chemistry & Immunodiagnostic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Clinical Chemistry & Immunodiagnostic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Clinical Chemistry & Immunodiagnostic Market

A detailed market share analysis in the Clinical Chemistry & Immunodiagnostic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Clinical Chemistry & Immunodiagnostic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Clinical Chemistry & Immunodiagnostic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Clinical Chemistry & Immunodiagnostic Market

A strategic analysis of the Clinical Chemistry & Immunodiagnostic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Clinical Chemistry & Immunodiagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accurex Biomedical Private Limited, Agappe Diagnostics Ltd., Bio-Rad Laboratories, Inc., bioMerieux SA, Cardinal Health, Inc., Chengdu Seamaty Technology Co., Ltd., Danaher Corporation, DiaSorin S.p.A, ELITechGroup by Bruker Corporation, F. Hoffmann-La Roche Ltd., GenviewDX, H.U. Group Holdings Inc., Hitachi, Ltd., HORIBA, Ltd., Immuno Diagnostics Pvt. Ltd., Medix Biochemica AB, QIAGEN N.V., Quest Diagnostics Incorporated, QuidelOrtho Corporation, Sekisui Medical Co. Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens AG, Thermo Fisher Scientific Inc., and viSole The Solution.

Market Segmentation & Coverage

This research report categorizes the Clinical Chemistry & Immunodiagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Instruments and Reagents.
  • Based on End-user, market is studied across Diagnostic Laboratories and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising elderly population and growing prevalence of chronic diseases
      • 5.1.1.2. Favorable government initiatives for adoption of clinical chemistry & immunodiagnostic techniques
      • 5.1.1.3. Growing importance and awareness of point-of-care testing
    • 5.1.2. Restraints
      • 5.1.2.1. Issues associated with chemistry and immunodiagnostic product recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing technological advancements in clinical chemistry and immunodiagnostic instruments
      • 5.1.3.2. Growing potential of clinical chemistry & immunodiagnostic in telemedicine and personalized therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent and varying regulatory standards for product development and commercialization
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Adoption of modular and scalable systems that easily integrate with existing hospital information systems
    • 5.2.2. End-user: Growing focus on advanced technological integration in instruments
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Clinical Chemistry & Immunodiagnostic Market, by Product Type

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents

7. Clinical Chemistry & Immunodiagnostic Market, by End-user

  • 7.1. Introduction
  • 7.2. Diagnostic Laboratories
  • 7.3. Hospitals

8. Americas Clinical Chemistry & Immunodiagnostic Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Clinical Chemistry & Immunodiagnostic Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Clinical Chemistry & Immunodiagnostic Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Introduction of Beckman Coulter's DxC 500 AU Chemistry Analyzer
    • 11.3.2. Strategic Partnership Between Fujirebio Holdings and Agappe Diagnostics to Revolutionize Chemiluminescence Immunoassay Production in India
    • 11.3.3. Roche Expands Diagnostics Portfolio with Acquisition of LumiraDx Point of Care Technology
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Accurex Biomedical Private Limited
  • 3. Agappe Diagnostics Ltd.
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux SA
  • 6. Cardinal Health, Inc.
  • 7. Chengdu Seamaty Technology Co., Ltd.
  • 8. Danaher Corporation
  • 9. DiaSorin S.p.A
  • 10. ELITechGroup by Bruker Corporation
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. GenviewDX
  • 13. H.U. Group Holdings Inc.
  • 14. Hitachi, Ltd.
  • 15. HORIBA, Ltd.
  • 16. Immuno Diagnostics Pvt. Ltd.
  • 17. Medix Biochemica AB
  • 18. QIAGEN N.V.
  • 19. Quest Diagnostics Incorporated
  • 20. QuidelOrtho Corporation
  • 21. Sekisui Medical Co. Ltd.
  • 22. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 23. Siemens AG
  • 24. Thermo Fisher Scientific Inc.
  • 25. viSole The Solution

LIST OF FIGURES

  • FIGURE 1. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET RESEARCH PROCESS
  • FIGURE 2. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET DYNAMICS
  • TABLE 7. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023